Current Report Filing (8-k)
August 07 2020 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
AND EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): August 4, 2020
SHINECO,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37776
|
|
52-2175898
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
Room
1001, Building T5,
DaZu
Square, Daxing District,
Beijing,
People’s Republic of China
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (+86) 10-87227366
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
TYHT
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
|
Effective
August 4, 2020, the Board of Directors (the “Board”) of Shineco, Inc. (the “Company”) accepted
the resignation of Mr. Yuying Zhang, the Company’s Chief Executive Officer. The resignation was not because of any disagreement
with the Company known to the Board of on any matter related to the Company’s operations, policies, or practices. In connection
with Mr. Zhang’s resignation there is no arrangement or understanding between Mr. Zhang and the Company.
Effective
August 4, 2020, the Board of Directors unanimously appointed Mr. Fengming Liu, as the Chief Executive Officer (“CEO”)
and Chief Scientist (“CS”). There is no arrangement or understanding between Mr. Liu and any other person pursuant
to which Mr. Liu was selected as CEO and CS, there is no family relationship between Mr. Liu and any director or officer of the
Company, and Mr. Liu is not party to any transaction in which the Company is a participant. Mr. Liu will continue to be entitled
to participate in all employment benefit plans and policies of the Company generally available. Mr. Liu’s compensation will
initially be $1. The Company and Mr. Liu and discussing his future compensation and upon finalization will file a Form 8-k to
disclose the agreed upon compensation.
Mr.
Liu, age 60, has been the Chief Executive Officer and the Director of R&D for Changzhou Biowin Pharmaceutical Company in Changzhou,
China since year of 2012 and was responsible for the development of new products in in-vitro diagnostics and overall management
of the company. Mr. Liu was the Executive Director of Beijing Yili Biotech Institute Company in Beijing, China from 2000 to 2010
and he was responsible for the research and development of pharmaceutical products and overall management of the company. Mr.
Liu has made great contributions in many fields, including pharmaceuticals, diagnostic products and medical devices, and successfully
led or joined in 43 biomedical related market approvals by the Chinese FDA so far. Due to his great achievement in biomedical
sciences, Mr. Liu has been approved as the Principle Investigator for five of the national key projects from the Chinese National
Development and Reform Commission and Ministry of Science and Technology of China. Mr. Liu is a national leading expert in this
field and received several national awards including the Chinese Scientific Person of the Year in 2014, 2016 Overseas Chinese
Innovation Talent Award, 2018 Industry University Cooperation Innovation Award and Top 10 Innovators of the Chinese Health Industry
2019. Mr. Liu was a medical doctor prior to 1992 and Mr. Liu received his medical degree from the Peking Union Medical College,
the most prestigious medical college in China. Mr. Liu received his post-doctoral training at Creighton University and Dartmouth
College from 1992-1997. Mr Liu served as assistant professor and research investigator at Creighton University, Dartmouth College
and Millennium Pharmaceutical Inc. in the USA from 1997 to 1999. Mr. Liu is a business focused and profitability-driven management
executive with a track record of success at biomedical and pharmaceutical companies.
SIGNATURE
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
|
SHINECO,
INC.
|
|
|
|
|
By:
|
/s/
Fengming Liu
|
|
Name:
|
Fengming
Liu
|
|
Its:
|
Chief
Executive Officer
|
Dated:
August 7, 2020
Shineco (NASDAQ:TYHT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shineco (NASDAQ:TYHT)
Historical Stock Chart
From Apr 2023 to Apr 2024